Currently Enrolling Trials

Interested in learning about a non-hormonal, investigational drug? The SKYLIGHT clinical study is seeking eligible candidates with hot flashes. To learn more about this study, click here.

Osteoporosis is a bone disease in which the body can’t create new bone fast enough to keep up with loss of old bone. This results in bones that are weak and brittle, causing them to break easily. Osteoporosis is most likely to result in a break in the spine, hip or wrist, but other areas can be affected too. This clinical research study is evaluating an investigational patch medication in post menopausal women with osteoporosis. The study doctors want to compare the effectiveness of the patch verion to the approved injectable version of the drug. 

If you take part in this study, you’ll be assigned to 1 or 2 study groups. One of these groups will receive the investgational patch medication, while the other will receive the approved injectable medication. You will receive study drug for up to 12 months at no cost. The study drug will either be a patch that you wear on your thigh for 5 minutes or an injection. You’ll use it daily. You will participate for up to 15 months and have 17 visits at the study clinic. 

Consider joining the TRAVERSE research study for men age 45-80 who have symptoms of low testosterone (hypogonadism) and have a history or risk of heart disease or stroke.

If you volunteer and qualify, your participation will last up to approximately 5 years. 

Alzheimer’s Disease causes the brain cells to die and bring cognitive damages such as memory loss. Scientific experts have discovered that AR1001 may help nourish and protect the brain cells through increasing the blood flow to the brain. The purpose of this study is to find out if an investigational new drug called AR1001 can help people with Alzheimer’s Disease and if it is safe. 

To participate, you must:

  • Be 55 – 80 years old.
  • Have been diagnosed with mild to moderate Alzheimer’sdisease.
  • Have a caregiver or family member who will attend study visits, report on daily activities and oversee you taking medication

This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab (Repatha) on major cardiovascular events in adults without a prior myocardial infarction (MI) or stroke who are at high risk of a cardiovascular event. To learn more, click here

Have Questions?

Send us a message by clicking the “contact us” button or call us at +1-843-851-7098.